ACE2, TMPRSS2 distribution and extrapulmonary organ injury in patients with COVID-19
At the end of 2019, the coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in China. Currently, it is breaking out globally and posing a serious threat to public health. The typically clinical characteristics of COVID-19 patients were...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-11-01
|
Series: | Biomedicine & Pharmacotherapy |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0753332220308714 |
id |
doaj-d0595adeb7a14742abe9db3de2d4c643 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Mengzhen Dong Jie Zhang Xuefeng Ma Jie Tan Lizhen Chen Shousheng Liu Yongning Xin Likun Zhuang |
spellingShingle |
Mengzhen Dong Jie Zhang Xuefeng Ma Jie Tan Lizhen Chen Shousheng Liu Yongning Xin Likun Zhuang ACE2, TMPRSS2 distribution and extrapulmonary organ injury in patients with COVID-19 Biomedicine & Pharmacotherapy SARS-CoV-2 COVID-19 ACE2 TMPRSS2 Extrapulmonary organs Clinical management |
author_facet |
Mengzhen Dong Jie Zhang Xuefeng Ma Jie Tan Lizhen Chen Shousheng Liu Yongning Xin Likun Zhuang |
author_sort |
Mengzhen Dong |
title |
ACE2, TMPRSS2 distribution and extrapulmonary organ injury in patients with COVID-19 |
title_short |
ACE2, TMPRSS2 distribution and extrapulmonary organ injury in patients with COVID-19 |
title_full |
ACE2, TMPRSS2 distribution and extrapulmonary organ injury in patients with COVID-19 |
title_fullStr |
ACE2, TMPRSS2 distribution and extrapulmonary organ injury in patients with COVID-19 |
title_full_unstemmed |
ACE2, TMPRSS2 distribution and extrapulmonary organ injury in patients with COVID-19 |
title_sort |
ace2, tmprss2 distribution and extrapulmonary organ injury in patients with covid-19 |
publisher |
Elsevier |
series |
Biomedicine & Pharmacotherapy |
issn |
0753-3322 |
publishDate |
2020-11-01 |
description |
At the end of 2019, the coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in China. Currently, it is breaking out globally and posing a serious threat to public health. The typically clinical characteristics of COVID-19 patients were fever and respiratory symptoms, and a proportion of patients were accompanied by extrapulmonary symptoms including cardiac injury, kidney injury, liver injury, digestive tract injury, and neurological symptoms. Angiotensin converting enzyme 2 (ACE2) has been proven to be a major receptor for SARS-CoV-2 and could mediate virus entry into cells. And transmembrane protease serine 2 (TMPRSS2) could cleave the spike (S) protein of SARS-CoV-2, which facilitates the fusion of SARS-CoV-2 and cellular membranes. The mRNA expressions of both ACE2 and TMPRSS2 were observed in the heart, digestive tract, liver, kidney, brain and other organs. SARS-CoV-2 may have a capacity to infect extrapulmonary organs due to the expressions of ACE2 and TMPRSS2 in the cells and tissues of these organs. It seems that there is a potential involvement of ACE2 and TMPRSS2 expressions in the virus infection of extrapulmonary organs and the manifestation of symptoms related to these organs in patients with COVID-19. Here, we revealed the expressions of ACE2 and TMPRSS2 in extrapulmonary organs, and we also summarized the clinical manifestation and the management of extrapulmonary complications in patients with COVID-19. |
topic |
SARS-CoV-2 COVID-19 ACE2 TMPRSS2 Extrapulmonary organs Clinical management |
url |
http://www.sciencedirect.com/science/article/pii/S0753332220308714 |
work_keys_str_mv |
AT mengzhendong ace2tmprss2distributionandextrapulmonaryorganinjuryinpatientswithcovid19 AT jiezhang ace2tmprss2distributionandextrapulmonaryorganinjuryinpatientswithcovid19 AT xuefengma ace2tmprss2distributionandextrapulmonaryorganinjuryinpatientswithcovid19 AT jietan ace2tmprss2distributionandextrapulmonaryorganinjuryinpatientswithcovid19 AT lizhenchen ace2tmprss2distributionandextrapulmonaryorganinjuryinpatientswithcovid19 AT shoushengliu ace2tmprss2distributionandextrapulmonaryorganinjuryinpatientswithcovid19 AT yongningxin ace2tmprss2distributionandextrapulmonaryorganinjuryinpatientswithcovid19 AT likunzhuang ace2tmprss2distributionandextrapulmonaryorganinjuryinpatientswithcovid19 |
_version_ |
1721434817918140416 |
spelling |
doaj-d0595adeb7a14742abe9db3de2d4c6432021-05-20T07:43:46ZengElsevierBiomedicine & Pharmacotherapy0753-33222020-11-01131110678ACE2, TMPRSS2 distribution and extrapulmonary organ injury in patients with COVID-19Mengzhen Dong0Jie Zhang1Xuefeng Ma2Jie Tan3Lizhen Chen4Shousheng Liu5Yongning Xin6Likun Zhuang7Department of Infectious Diseases, Qingdao Municipal Hospital, Qingdao University, Qingdao, China; Institute of Hepatology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China; Digestive Disease Key Laboratory of Qingdao, Qingdao, ChinaDepartment of Infectious Diseases, Qingdao Municipal Hospital, Qingdao University, Qingdao, China; Institute of Hepatology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China; Digestive Disease Key Laboratory of Qingdao, Qingdao, ChinaDepartment of Infectious Diseases, Qingdao Municipal Hospital, Qingdao University, Qingdao, China; Institute of Hepatology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China; Digestive Disease Key Laboratory of Qingdao, Qingdao, ChinaDepartment of Infectious Diseases, Qingdao Municipal Hospital, Qingdao University, Qingdao, China; Institute of Hepatology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China; Digestive Disease Key Laboratory of Qingdao, Qingdao, ChinaDepartment of Infectious Diseases, Qingdao Municipal Hospital, Qingdao University, Qingdao, China; Institute of Hepatology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China; Digestive Disease Key Laboratory of Qingdao, Qingdao, ChinaDepartment of Infectious Diseases, Qingdao Municipal Hospital, Qingdao University, Qingdao, China; Institute of Hepatology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China; Digestive Disease Key Laboratory of Qingdao, Qingdao, ChinaDepartment of Infectious Diseases, Qingdao Municipal Hospital, Qingdao University, Qingdao, China; Institute of Hepatology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China; Digestive Disease Key Laboratory of Qingdao, Qingdao, China; Corresponding authors at: Department of Infectious Disease and Institute of Hepatology, Qingdao Municipal Hospital, Qingdao University, Digestive Disease Key Laboratory of Qingdao, Qingdao, 266071, China.Department of Infectious Diseases, Qingdao Municipal Hospital, Qingdao University, Qingdao, China; Institute of Hepatology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China; Digestive Disease Key Laboratory of Qingdao, Qingdao, China; Corresponding authors at: Department of Infectious Disease and Institute of Hepatology, Qingdao Municipal Hospital, Qingdao University, Digestive Disease Key Laboratory of Qingdao, Qingdao, 266071, China.At the end of 2019, the coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in China. Currently, it is breaking out globally and posing a serious threat to public health. The typically clinical characteristics of COVID-19 patients were fever and respiratory symptoms, and a proportion of patients were accompanied by extrapulmonary symptoms including cardiac injury, kidney injury, liver injury, digestive tract injury, and neurological symptoms. Angiotensin converting enzyme 2 (ACE2) has been proven to be a major receptor for SARS-CoV-2 and could mediate virus entry into cells. And transmembrane protease serine 2 (TMPRSS2) could cleave the spike (S) protein of SARS-CoV-2, which facilitates the fusion of SARS-CoV-2 and cellular membranes. The mRNA expressions of both ACE2 and TMPRSS2 were observed in the heart, digestive tract, liver, kidney, brain and other organs. SARS-CoV-2 may have a capacity to infect extrapulmonary organs due to the expressions of ACE2 and TMPRSS2 in the cells and tissues of these organs. It seems that there is a potential involvement of ACE2 and TMPRSS2 expressions in the virus infection of extrapulmonary organs and the manifestation of symptoms related to these organs in patients with COVID-19. Here, we revealed the expressions of ACE2 and TMPRSS2 in extrapulmonary organs, and we also summarized the clinical manifestation and the management of extrapulmonary complications in patients with COVID-19.http://www.sciencedirect.com/science/article/pii/S0753332220308714SARS-CoV-2COVID-19ACE2TMPRSS2Extrapulmonary organsClinical management |